European medicinal cannabis company Curaleaf International has introduced four branded flower strains to the Australian market through a distribution partnership with Canngea, with additional products planned for release.
The company described the move as its entry into "one of the world's fastest-growing medical cannabis markets" and the start of a broader footprint in Australia.
"Over the coming months, patients and healthcare professionals in Australia can look forward to a broader portfolio and further innovative solutions… including precision-dosed inhalation formats and popular strains already widely prescribed across the UK, Germany, and other key European markets," the company said.
Curaleaf International Head Juan Martinez called the launch "a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines."
"We're committed to supporting Australian patients and healthcare professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains," he said.
Chairman and CEO Boris Jordan said: "Australia is an exciting and rapidly evolving market, expected to surpass $1 billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis.
"We're bringing a proven portfolio and a strong track record of innovation, with more to come."
Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK, cultivation and EU-GMP processing facilities in Portugal, an EU-GMP processing, quality assurance and research site in Spain, Four20 Pharma – a wholesaler and distributor in Germany, a Polish wholesaler and clinic and the EU-GMP producer Northern Green Canada.
